Graft vs Host Disease

Mesoblast has resubmitted its biologics license application (BLA) to the US Food and Drug Administration (FDA) for approval of remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).  Survival outcomes have not improved over the past two decades for the most severe forms of SR- aGVHD, a life-threatening complication of […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we learned the shocking statistic that a third of scientific researchers have, or know a close colleague who has, […]

News round-up for 7-11 November by DDW Digital Content Editor Diana Spencer  This week we learned the shocking statistic that a third of scientific researchers have, or know a close colleague who has, experienced abuse after posting research online.  It wasn’t all bad news, however, as top pharma CEOs committed to reducing the industry’s carbon emissions and a […]

BioSenic’s arsenic trioxide (ATO) autoimmune disease platform has completed a successful Phase IIb trial in chronic Graft vs Host Disease (cGVHD) and is preparing to move to a Phase III trial.  The BioSenic autoimmune platform was created by Medsenic to target systemic autoimmune diseases using ATO as an active anti-inflammatory and immunomodulatory agent.  The Phase […]